19.6 C
New York
Saturday, June 3, 2023

What Are The Chances Of Allogene Therapeutics Inc. (NASDAQ: ALLO) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Allogene Therapeutics Inc. (ALLO) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.12, or 1.96%, to $6.25. The Allogene Therapeutics Inc. has recorded 36,172 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.

Sponsored

Stocks Info

As a NASDAQ listed company, ALLO falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $6.13 and fluctuated between $6.61 as its day high and $6.12 as its day low. The current market capitalization of Allogene Therapeutics Inc. is $907.24M. A total of 2.97 million shares were traded on the day, compared to an average of 2.09M shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, ALLO has seen 5 BUY and 4 SELL insider trades, representing the acquisition of 3,245,232 and the disposition of 90,198 shares. Over the last 12 months, there were 12 BUYs and 18 SELLs from insiders. Insiders purchased 3,684,122 shares during that period but sold 176,732.

In the most recent transaction, Bhavnagri Veer sold 3,000 shares of ALLO for 6.85 per share on Feb 13. After the transaction, the General Counsel now owns 577,677 company shares. In a previous transaction on Jan 17, Bhavnagri Veer sold 3,000 shares at 7.04 per share. ALLO shares that General Counsel owns now total 580,677.

Among the insiders who sold shares, Bhavnagri Veer disposed of 5,602 shares on Dec 15 at a per-share price of $7.53. This resulted in the General Counsel holding 583,677 shares of ALLO after the transaction. In another insider transaction, WITTE OWEN N. sold 5,000 shares at $17.25 per share on Aug 12. Company shares held by the Director now total 218,271.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for ALLO in the last 3 months, the mean price target is $16.91 with high estimates of $35.00 and low estimates of $6.00. In terms of 52-week highs and lows, ALLO has a high of $17.49 and a low of $4.42.

As of this writing, ALLO has an earnings estimate of -$0.59 per share for the current quarter. EPS was calculated based on a consensus of 19 estimates, with a high estimate of -$0.52 per share and a lower estimate of -$0.68. The company reported an EPS of -$0.66 in the last quarter, which was 5.70% higher than expectations of -$0.7.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ALLO’s latest balance sheet shows that the firm has $809.48M in Cash & Short Term Investments as of fiscal 2021. There were $69.93M in debt and $48.17M in liabilities at the time. Its Book Value Per Share was $4.10, while its Total Shareholder’s Equity was $916.41M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.41.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles